Recombinant Human Antibody for COVID-19 Research

---

Clone RV6 has been tested to bind to S2 subunit in the form of trimeric SARS-CoV-2 Spike S2 subunit protein, and show neutralizing activity.

Clone RV82 has been tested to bind to S2 subunit of SARS-Cov-2 S protein, and show NO neutralizing activity. This antibody has been tested to discriminate SARS-CoV-2 from SARS spike (2003 strain).

Clone RV57 has been tested to bind to receptor binding domain (RBD) of SARS-CoV-2 Spike protein, and show neutralizing activity.

Clone RV94 has been tested to bind to N-terminal domain (NTD) of SARS-CoV-2 S protein, and show neutralizing activity.

Clone RV20 binds to SARS-CoV-2 nucleocapsid (N) protein with specificity on NTD

Clone CR3022 has been tested to bind to receptor binding domain (RBD) of S proteins of SARS-CoV and SARS-CoV-2, and show neutralizing activity against SARS-Cov, but not SARS-Cov-2.

Clone RV88 has been tested to bind to RBD of SARS (2003 strain), SARS-CoV-2 Wuhan Strain and SARS-CoV-2 B.1.351 South Africa (or Beta variant), and show neutralizing activity against these three pseudoviruses (Catalog # P14N41, G99O57 and V44X39), and SARS-CoV-2 Delta variant (Catalog # D33Z75).

Clone RV38 has been tested to bind to receptor binding domain (RBD) of SARS-Cov (2003 strain) S protein, and show neutralizing activity.

Clone RV45 has been tested to bind to trimeric form of MERS-Cov S protein, and show neutralizing activity.